Literature DB >> 30888052

Accelerated thymopoiesis and improved T-cell responses in HLA-A2/-DR2 transgenic BRGS-based human immune system mice.

Guillemette Masse-Ranson1,2,3, Mathilde Dusséaux1,2, Oriane Fiquet1,2, Sylvie Darche1,2, Maud Boussand1,2, Yan Li1,2, Silvia Lopez-Lastra1,2, Nicolas Legrand4, Erwan Corcuff4, Antoine Toubert5,6, Mireille Centlivre3, Timothée Bruel3,7,8, Hergen Spits9, Olivier Schwartz3,7,8, Yves Lévy3,10,11, Hélène Strick-Marchand1,2, James P Di Santo1,2.   

Abstract

Human immune system (HIS) mouse models provide a robust in vivo platform to study human immunity. Nevertheless, the signals that guide human lymphocyte differentiation in HIS mice remain poorly understood. Here, we have developed a novel Balb/c Rag2-/- Il2rg-/- SirpaNOD (BRGS) HIS mouse model expressing human HLA-A2 and -DR2 transgenes (BRGSA2DR2). When comparing BRGS and BRGSA2DR2 HIS mice engrafted with human CD34+ stem cells, a more rapid emergence of T cells in the circulation of hosts bearing human HLA was shown, which may reflect a more efficient human T-cell development in the mouse thymus. Development of CD4+ and CD8+ T cells was accelerated in BRGSA2DR2 HIS mice and generated more balanced B and T-cell compartments in peripheral lymphoid organs. Both B- and T-cell function appeared enhanced in the presence of human HLA transgenes with higher levels of class switched Ig, increased percentages of polyfunctional T cells and clear evidence for antigen-specific T-cell responses following immunization. Taken together, the presence of human HLA class I and II molecules can improve multiple aspects of human B- and T-cell homeostasis and function in the BRGS-based HIS mouse model.
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Animal models; Humanized mice; Lymphocyte development

Mesh:

Substances:

Year:  2019        PMID: 30888052     DOI: 10.1002/eji.201848001

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

Review 1.  Humanized mouse model: a review on preclinical applications for cancer immunotherapy.

Authors:  Ling Yin; Xue-Jing Wang; De-Xi Chen; Xiao-Ni Liu; Xiao-Jun Wang
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

Review 2.  The mouse resource at National Resource Center for Mutant Mice.

Authors:  Cunxiang Ju; Juan Liang; Mingkun Zhang; Jinlong Zhao; Ling'en Li; Shuai Chen; Jing Zhao; Xiang Gao
Journal:  Mamm Genome       Date:  2022-02-09       Impact factor: 2.957

3.  Advanced Immune Cell Profiling by Multiparameter Flow Cytometry in Humanized Patient-Derived Tumor Mice.

Authors:  Christina Bruss; Kerstin Kellner; Olaf Ortmann; Stephan Seitz; Gero Brockhoff; James A Hutchinson; Anja Kathrin Wege
Journal:  Cancers (Basel)       Date:  2022-04-28       Impact factor: 6.575

Review 4.  Innovations, challenges, and minimal information for standardization of humanized mice.

Authors:  Renata Stripecke; Christian Münz; Jan Jacob Schuringa; Karl-Dimiter Bissig; Brian Soper; Terrence Meeham; Leonard Shultz; Li-Chin Yao; James P Di Santo; Michael Brehm; Estefania Rodriguez; Anja Kathrin Wege; Dominique Bonnet; Silvia Guionaud; Kristina E Howard; Scott Kitchen; Florian Klein; Kourosh Saeb-Parsy; Johannes Sam; Amar Deep Sharma; Andreas Trumpp; Livio Trusolino; Carol Bult
Journal:  EMBO Mol Med       Date:  2020-06-24       Impact factor: 12.137

Review 5.  Advances in Humanized Mouse Models to Improve Understanding of HIV-1 Pathogenesis and Immune Responses.

Authors:  Amy Gillgrass; Jocelyn M Wessels; Jack X Yang; Charu Kaushic
Journal:  Front Immunol       Date:  2021-03-05       Impact factor: 7.561

6.  Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes.

Authors:  Juan A Marín-Jiménez; Anna Capasso; Matthew S Lewis; Stacey M Bagby; Sarah J Hartman; Jeremy Shulman; Natalie M Navarro; Hui Yu; Chris J Rivard; Xiaoguang Wang; Jessica C Barkow; Degui Geng; Adwitiya Kar; Ashley Yingst; Dejene M Tufa; James T Dolan; Patrick J Blatchford; Brian M Freed; Raul M Torres; Eduardo Davila; Jill E Slansky; Roberta Pelanda; S Gail Eckhardt; Wells A Messersmith; Jennifer R Diamond; Christopher H Lieu; Michael R Verneris; Jing H Wang; Katja Kiseljak-Vassiliades; Todd M Pitts; Julie Lang
Journal:  Front Immunol       Date:  2021-03-29       Impact factor: 7.561

7.  Epitope convergence of broadly HIV-1 neutralizing IgA and IgG antibody lineages in a viremic controller.

Authors:  Valérie Lorin; Ignacio Fernández; Guillemette Masse-Ranson; Mélanie Bouvin-Pley; Luis M Molinos-Albert; Cyril Planchais; Thierry Hieu; Gérard Péhau-Arnaudet; Dominik Hrebík; Giulia Girelli-Zubani; Oriane Fiquet; Florence Guivel-Benhassine; Rogier W Sanders; Bruce D Walker; Olivier Schwartz; Johannes F Scheid; Jordan D Dimitrov; Pavel Plevka; Martine Braibant; Michael S Seaman; François Bontems; James P Di Santo; Félix A Rey; Hugo Mouquet
Journal:  J Exp Med       Date:  2022-03-01       Impact factor: 17.579

8.  Comparing Current and Next-Generation Humanized Mouse Models for Advancing HIV and HIV/Mtb Co-Infection Studies.

Authors:  Madeleine Lepard; Jack X Yang; Sam Afkhami; Aisha Nazli; Anna Zganiacz; Shangguo Tang; Margaret Wa Yan Choi; Fatemah Vahedi; Alexandre Deshiere; Michel J Tremblay; Zhou Xing; Charu Kaushic; Amy Gillgrass
Journal:  Viruses       Date:  2022-08-30       Impact factor: 5.818

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.